The iQue® has a novel solution to disrupt the traditional antibody discovery workflow. Success of antibody-based block-buster therapeutics for autoimmune diseases, inflammatory diseases and immune-oncology have accelerated high stakes monoclonal antibody (mAb) discovery—a time-consuming process in which therapeutic antibody candidates are initially generated using hybridoma technology or primary B cell screening after antigen immunization.
The primary screens identify clones with specific attributes (binding specificity, cross species reactivity, selectivity and affinity). Potential candidates from the screen are then assessed for a variety of critical parameters for lead molecule generation such as IgG isotyping, antibody quantification, and cell number/health.
This process typically involves single-endpoint assays requiring sample dilution and multiple washes. That all changes with the iQue® Mouse IgG Type and Titer Kit, a patented high throughput, multiplexed assay with a wide dynamic range requiring no sample dilution or wash steps. The simple mix-and-read workflow simultaneously measures five endpoints: Enables quick differentiation between monoclonal and polyclonal wells Determines IgG quantity for qualifying stable clones and for downstream functional assays Provides IgG isotype information to facilitate primer design for PCR-mediated gene cloning Monitors both cell proliferation and cell health prior to RNA isolation prior to PCR-mediated cloning
The Mouse IgG Type and Titer assay is part of the iQue®’s integrated antibody discovery platform technology. The iQue® can acquire data in as little as 20 minutes per 384-well plate, while Forecyt® software provides powerful data mining tools for large hybridoma/B-cell screening studies.
Forecyt®’s Panorama feature provides interactive and visual multi-plate data analysis including profile maps with user-specified criteria to quickly identify samples containing the desired IgG isotype, antibody concentration and cell health, critical for analyzing data from large, multi-plate screening campaigns. The total time from samples to actionable data is less than 100 minutes.